Candesartan cilexetil: an update
- PMID: 21651457
- DOI: 10.1517/14656566.2011.587000
Candesartan cilexetil: an update
Abstract
Introduction: Candesartan cilexetil is one of the most often-used first-line drugs regarding the management of arterial hypertension. Moreover, this drug has proven its effectiveness in chronic heart failure and exerts beneficial effects in diabetes, stroke, dementia and atrial fibrillation.
Areas covered: This review focuses on the use of candesartan cilexetil in Phase II and Phase III trials and their implications for clinical usage in the treatment of arterial hypertension and heart failure. The usage of candesartan cilexetil in patients with stroke, migraine or atrial fibrillation, hypertrophy obstructive or nonobstructive cardiomyopathy and diabetic or non diabetic renal diseases will be discussed. Relevant publications were identified by an extensive Medline search.
Expert opinion: Candesartan cilexetil is a highly effective ARB for the treatment of arterial hypertension and heart failure. Also, recent trials have suggested beneficial effects in diabetic patients, patients with nondiabetic renal diseases, stroke, migraine and atrial fibrillation.
Similar articles
-
Candesartan: widening indications for this angiotensin II receptor blocker?Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197. Expert Opin Pharmacother. 2009. PMID: 19563275 Review.
-
Differential clinical profile of candesartan compared to other angiotensin receptor blockers.Vasc Health Risk Manag. 2011;7:749-59. doi: 10.2147/VHRM.S22591. Epub 2011 Dec 12. Vasc Health Risk Manag. 2011. PMID: 22241949 Free PMC article. Review.
-
Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.Curr Med Res Opin. 2007 Jul;23(7):1693-705. doi: 10.1185/030079907x210723. Curr Med Res Opin. 2007. PMID: 17588300 Review.
-
Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.Am J Cardiovasc Drugs. 2010;10(5):335-42. doi: 10.2165/11206300-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20860416 Review.
-
Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.Pharmacoeconomics. 2006;24(12):1249-72. doi: 10.2165/00019053-200624120-00008. Pharmacoeconomics. 2006. PMID: 17129078 Review.
Cited by
-
Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction.J Am Heart Assoc. 2022 Aug 2;11(15):e024285. doi: 10.1161/JAHA.121.024285. Epub 2022 Jul 19. J Am Heart Assoc. 2022. PMID: 35862154 Free PMC article.
-
Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity.Front Immunol. 2022 May 20;13:870627. doi: 10.3389/fimmu.2022.870627. eCollection 2022. Front Immunol. 2022. PMID: 35669789 Free PMC article.
-
Quantification of Candesartan in Mouse Plasma by MALDI-TOFMS and in Tissue Sections by MALDI-Imaging Using the Stable-Isotope Dilution Technique.Mass Spectrom (Tokyo). 2013;2(1):A0021. doi: 10.5702/massspectrometry.A0021. Epub 2013 Jun 1. Mass Spectrom (Tokyo). 2013. PMID: 24860711 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical